Biopsy Devices Market Size, Share, Growth Factors, Trends and Forecast 2026-2034

According to IMARC Group, the global Biopsy Devices Market Size reached USD 2.94 Billion in 2025 and is projected to reach USD 4.77 Billion by 2034, expanding at a CAGR of 5.36% during 2026-2034. This robust Biopsy Devices Market Growth reflects rising global cancer incidence, growing adoption of minimally invasive procedures, and the rapid integration of image-guided and AI-assisted biopsy techniques across healthcare systems worldwide.

Biopsy Devices Industry Overview

Biopsy devices are medical instruments used to extract tissue or cell samples from the body for laboratory examination, primarily to diagnose cancer and other diseases. The category spans surgical instruments, core and fine-needle biopsy devices, vacuum-assisted systems, and image-guidance platforms that together support accurate, minimally invasive sampling across a broad range of clinical indications.

Biopsy devices are deployed across a broad continuum of use cases:

• Oncology diagnostics: Breast, lung, prostate, colorectal, and lymph-node tumour sampling for definitive histopathology
• Minimally invasive procedures: Core-needle, vacuum-assisted, and percutaneous techniques enabling outpatient workflows
• Image-guided biopsy: Stereotactic, ultrasound, and MRI-guided platforms achieving sampling accuracy exceeding 95% in lesions under 10 mm
• Liquid biopsy: Circulating tumour DNA (ctDNA) analysis as a complementary modality across oncology indications
• Endoscopic and interventional applications: Gastroenterology, pulmonology, and urology biopsy procedures using forceps and needle-based systems

Global Biopsy Devices Market Size Key Statistics

Below are the key Biopsy Devices Market statistics drawn from IMARC Group's comprehensive market analysis:

Key Market Drivers Biopsy Devices Market Trends in 2026

Several powerful forces are shaping Biopsy Devices Market Trends and fuelling sustained growth expectations across global oncology diagnostics and interventional medicine:

1. Rising Global Cancer Incidence

The WHO recorded over 20 million new cancer cases globally in 2022, with breast, lung, and prostate cancers leading, and cases are projected to rise to 35 million by 2050. This expanding disease burden is generating sustained demand for accurate, timely diagnostic tissue sampling across healthcare systems worldwide, directly supporting Biopsy Devices Market Growth.

2. Shift to Minimally Invasive Procedures

Core-needle, vacuum-assisted, and percutaneous techniques have largely displaced open surgical biopsy in many indications, reducing patient recovery time, lowering complication rates, and enabling outpatient workflows. This transition continues to reshape procedure volumes and device demand across hospital and ambulatory settings.

3. Rapid Adoption of Image-Guided Biopsy

Stereotactic, ultrasound, and MRI-guided platforms now achieve sampling accuracy exceeding 95% in lesions under 10 mm, expanding biopsy use in early-stage cancer detection. This precision is a defining Biopsy Devices Market Trend, reinforcing the leadership of guidance-integrated platforms.

4. Liquid Biopsy as a Complementary Modality

Liquid biopsy, based on circulating tumour DNA (ctDNA) analysis from blood, is expanding its indications across oncology. A defining milestone was the July 2024 FDA approval of Guardant Health's Shield blood test, the first blood-based primary screening option approved for colorectal cancer in adults aged 45 and over, reinforcing the complementary role of liquid biopsy alongside tissue-based sampling.

5. AI and Machine Learning Integration in Biopsy Guidance

Artificial intelligence is transforming biopsy workflows through automated lesion detection, real-time targeting, and post-procedure pathology correlation. AI-powered breast tomosynthesis software is now deployed across dozens of countries, having supported the analysis of tens of millions of mammograms, with clinical studies showing improved radiologist sensitivity and reduced reading time.

6. Emergence of Robotic-Assisted Biopsy Platforms

Robotic-assisted prostate, breast, and lung biopsy platforms are gaining clinical traction, enabling sub-millimetre targeting accuracy. This technological convergence between robotics, imaging, and biopsy sampling is expanding the addressable market for premium, precision-guided device categories.

7. Expanding Cancer Screening Infrastructure in Emerging Markets

India, China, Brazil, and Indonesia represent structural growth markets as cancer screening programmes expand and private healthcare networks deploy advanced biopsy capabilities, broadening the global Biopsy Devices Market Share captured by emerging economies.

Key Market Segmentation

By Procedure Type

Surgical Biopsy - Largest Segment: Surgical Biopsy commands a 54.6% majority share in 2025, anchored by its diagnostic gold-standard status for many tumour types where excisional or incisional sampling provides definitive histopathology. The segment benefits from preference in complex breast, lymph-node, and lesion-staging cases.

Needle Biopsy: Needle Biopsy holds 45.4% share in 2025 and is the faster-growing procedure type, supported by core-needle and vacuum-assisted techniques that enable outpatient compatibility, lower complication rates, and reduced cost-per-procedure versus open surgical biopsy.

By Product

Biopsy Guidance Systems - Largest Segment: Biopsy Guidance Systems dominate the Biopsy Devices Market Share at 29.8% in 2025, reflecting the capital-intensive nature of stereotactic, ultrasound, and MRI-guided platforms. Hologic, BD, and Mammotome lead the breast guidance space, while GE and Siemens lead broader imaging-integrated platforms.

Biopsy Needles and Needle-Based Biopsy Guns: Biopsy Needles account for 24.6% and Needle-Based Biopsy Guns for 19.3% of the product market in 2025, scaling directly with overall procedure volumes across hospital and clinic settings.

Biopsy Forceps and Others: Biopsy Forceps hold 14.2% share, serving endoscopic gastroenterology and pulmonology applications, while Others, at 12.1%, include vacuum-assisted consumables and accessories.

By Application

• Breast Biopsy: The leading clinical application, reflecting high global breast cancer screening volumes and the widespread use of stereotactic and vacuum-assisted breast biopsy systems
• Lung Biopsy: A growing application supported by rising lung cancer incidence and expanding CT and navigational bronchoscopy-guided sampling
• Colorectal Biopsy: Benefiting from expanding colorectal cancer screening programmes and endoscopic biopsy forceps demand
• Prostate Biopsy: Supported by MRI-ultrasound fusion targeting and rising prostate cancer screening adoption
• Others: Includes dermatology, gynaecology, and lymph-node biopsy applications across specialty clinical settings

By Guidance Technique

• Ultrasound-Guided Biopsy: The leading guidance technique, widely used for thyroid, abdominal, breast, and prostate sampling
• Stereotactic-Guided Biopsy: Predominantly used in breast biopsy for precise lesion targeting
• MRI-Guided Biopsy: Increasingly adopted for lesions occult on ultrasound or mammography, particularly in breast and prostate indications
• Others: Includes CT-guided and navigational bronchoscopy-guided biopsy techniques

By End User

• Hospitals and Clinics: The leading end-user segment, operating high-volume biopsy programmes across oncology, radiology, and surgical departments
• Academic and Research Institutes: Early adopters of novel biopsy technologies, driving innovation through translational and clinical validation research
• Others: Includes ambulatory surgical centres and specialty diagnostic clinics

Regional Biopsy Devices Market Analysis

North America leads the global Biopsy Devices Market Share, anchored by the United States' advanced clinical infrastructure, high per-capita cancer screening rates, and the domestic presence of leading manufacturers including Hologic and BD.

Asia Pacific represents the fastest-growing regional market, driven by China's expanding hospital-tier diagnostic infrastructure, India's rapidly growing private diagnostics chains, and Japan's sustained investment in cancer-screening adherence under its universal healthcare coverage system.

Leading Players in the Global Biopsy Devices Industry

The global biopsy devices market features a concentrated core of medical technology leaders alongside emerging entrants in optical and robotic-assisted biopsy. The top five players collectively account for approximately 55-65% of global revenue. Key companies covered in the IMARC Group report include:

Latest Biopsy Devices Market Industry Developments

January 2026 - BD (Becton Dickinson)

BD received FDA clearance for its EnCor EnCompass breast biopsy system, marking the official launch phase of its next-generation multi-modality vacuum-assisted platform.

2025 - Hologic, Inc.

Hologic advanced its breast imaging portfolio through AI-driven solutions designed to improve workflow efficiency and support enhanced cancer detection and risk assessment.

2024 - Boston Scientific Corporation

Boston Scientific announced plans to acquire Axonics, Inc. for USD 3.7 Billion, expanding its medical device portfolio and strengthening its position in minimally invasive therapies.

July 2024 - Guardant Health

Guardant Health's Shield blood test received FDA approval as the first blood-based primary screening option for colorectal cancer in adults aged 45 and over, marking a milestone for liquid biopsy adoption.

June 2025 - Natera

Natera's Signatera MRD test secured broad Medicare coverage across colorectal, breast, bladder, ovarian, and lung cancers, plus pan-cancer immunotherapy monitoring, validated across more than 100 clinical studies.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Technology, Construction, Healthcare, Energy, Food Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104

Article source: https://article-realm.com/article/Business/84312-Biopsy-Devices-Market-Size-Share-Growth-Factors-Trends-and-Forecast-2026-2034.html